Diabetes Therapy
Glycemic control does not impact nontraditional cardiovascular disease risk factors equally
Published in Obesity and Diabetes Week, April 3rd, 2006
"The aim of this study was to determine the effect of basal insulin, alone or with a sensitizer, or a combination of oral agents on nontraditional risk factors for cardiovascular disease (CVD)."
V.A. Fonseca and colleagues at Tulane University conducted a randomized study including "57 patients with type 2 diabetes mellitus (T2DM) to either (1) continuous subcutaneous basal Lispro insulin at a single rate using an insulin pump (basal insulin) or (2) basal insulin and oral pioglitazone 10 mg...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Cardiovascular Disease
Cardiovascular mortality correlates with obesity in younger men more than in older men - Diabetes Pathogenesis
Diet-induced insulin resistance and obesity susceptibility is mediated by PEPCK overexpression - Insulin Resistance
Hyperphagia may be mediated by developmental perturbations in insulin signaling - Obesity Therapy
Gastric bypass 1-year outcomes for obese youth indicate health benefits offset risks - Obesity Therapy
Group training appears to be more helpful to the participants trying to reduce food portion - Aesthetic Medicine
Body contouring surgery is on the rise - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
